Untreated Rhesus Incompatibility Poses Risks to Future Pregnancies and Newborns
Medical experts have issued a stark warning that untreated Rhesus (Rh) incompatibility may seriously endanger both future pregnancies and the health of newborns. They are calling for intensified awareness campaigns to educate women and young girls about potential complications, stressing that early knowledge and proper counselling can help prevent avoidable fear, distress, and pregnancy-related issues.
The Science Behind Rh Incompatibility
The Rh factor is a protein found on red blood cells. Individuals who possess this protein are classified as Rh-positive, while those who lack it are Rh-negative. Challenges arise when an Rh-negative mother carries an Rh-positive baby, a trait typically inherited from the father. In such scenarios, the mother's immune system may identify the baby's blood cells as foreign and produce antibodies against them.
While the first pregnancy is often unaffected, subsequent Rh-positive pregnancies may be at significant risk. These antibodies can attack the baby's red blood cells, leading to severe health issues. The World Health Organisation recommends the use of RhD immunoglobulin (anti-D) for RhD-negative pregnant women to prevent sensitisation, which can result in haemolytic disease of the newborn. This guideline includes administration at approximately 28 weeks of pregnancy and within 72 hours after delivery if the baby is Rh-positive.
Expert Insights on Prevention and Management
Dr. Stanley Egbogu, a gynaecologist at Nnamdi Azikiwe University Teaching Hospital, explained that Rh-negative mothers are not inherently at higher risk when proper medical protocols are followed. He noted that complications primarily arise when sensitisation occurs, especially if the mother's immune system has already developed antibodies against Rh-positive blood cells.
"Timely testing of the baby's blood group after delivery and administration of anti-D immunoglobulin, commonly known as Rhogam, within 72 hours can prevent future complications," Dr. Egbogu stated. He added that women who receive the injection after childbirth significantly reduce the risk of problems in subsequent pregnancies, while those whose partners are also Rh-negative face no incompatibility risk at all.
Similarly, Dr. Muyideen Adelakun, a consultant obstetrician and gynaecologist at General Hospital Mushin, highlighted that Rh incompatibility mainly affects the unborn baby but can also cause lasting psychological distress for mothers. He explained that in severe cases, the mother's antibodies may destroy the baby's red blood cells, leading to conditions such as hydrops fetalis, where fluid accumulates in the baby's body, drastically reducing survival chances.
"About half of babies born alive with severe forms of the condition may not survive, but outcomes improve significantly with early detection and intervention," Adelakun emphasised. He added that even if Rhogam was not administered after a first pregnancy, careful monitoring in subsequent pregnancies can still enhance outcomes. In some instances, delivery may be induced early if the baby is stable, or the pregnancy closely managed if complications are detected.
The gynaecologist warned that untreated cases could lead to haemolytic disease of the newborn, brain damage, or heart failure. However, he stressed that with proper antenatal care, monitoring, and timely treatment, Rh-negative mothers can safely deliver healthy babies.
Personal Stories Highlighting the Need for Awareness
Mothers who shared their experiences with The Guardian underscored that earlier knowledge and counselling could help prevent avoidable fear and distress. Women living with the Rh-negative blood group recounted emotionally draining pregnancy journeys, even as health experts emphasised that most risks are manageable with proper monitoring and timely treatment.
When Florence Ayibe became pregnant with her second child, she anticipated an easier journey than her first, which had ended in an emergency delivery but with both mother and baby surviving. Unaware that her Rh-negative blood type could quietly influence her next pregnancy, she was shocked during a routine antenatal visit in her fifth month when doctors noticed signs that the baby might be anaemic.
Further tests revealed that Ayibe had developed antibodies after her first pregnancy, likely because she did not receive anti-D immunoglobulin in time after delivery. These antibodies were attacking the red blood cells of her unborn Rh-positive baby. "I had never even heard of the Rh factor before, and nobody explained it to me after my first child was born," she lamented.
What followed were weeks of fear, hospital visits, and constant monitoring. Instead of preparing for a new baby, Ayibe spent sleepless nights searching for answers and hoping for good news. Doctors closely monitored the pregnancy and eventually delivered the baby early to improve the child's chances. Her son was born weak and jaundiced, requiring urgent care in a neonatal unit.
"I kept blaming myself, but how could I know what no one told me? If I had known earlier, I might have been spared so much fear and sleepless nights. No woman should learn about the Rh factor when her baby is already fighting for life," Ayibe reflected. Today, both mother and child are doing well, and Ayibe now shares her story, urging expectant mothers to know their blood group early, ask questions during antenatal care, and ensure they receive anti-D injections when needed.
A similar sense of shock marked the experience of Nwadialor Glory (pseudonym), who did not expect a routine hospital visit to turn into one of the most frightening moments of her life. In her mid-20s, newly married and working on her undergraduate project, she became pregnant unexpectedly and went to a clinic seeking an abortion.
Initially, everything seemed straightforward until the doctor asked for her blood group. She could not recall ever being told she was Rh-negative, but a quick test confirmed it. What followed, she said, was not judgment but a detailed explanation that changed everything. The doctor informed her that because she was Rh-negative, terminating the pregnancy without proper precautions could expose her to Rh-positive foetal blood.
Such exposure could trigger her immune system to produce antibodies that might not affect her immediately but could harm future pregnancies, potentially leading to miscarriage or serious complications. "I didn't even understand half of it at first. All I knew was that the risks I thought I understood suddenly had consequences I had never heard about," she recalled.
Glory sat in silence as the implications sank in, realising that what she assumed was a private decision could affect the children she hopes to have in the future.
Conclusion
The experiences of these mothers and the insights from medical professionals highlight the critical need for early screening, education, and timely intervention regarding Rhesus incompatibility. By raising awareness and ensuring proper medical care, many of the associated risks can be effectively managed, allowing Rh-negative women to experience safer pregnancies and healthier outcomes for their newborns.
